Toxicity, safety, treatment compliance
deaths, neutropenia, Neutropenia, chest pain, vomiting, pyrexia, sepsis
DISEASE PROGRESSION, NEUTROPENIA, ADVERSE EVENTS, NEUTROPENIA, SEPSIS
RT metrics: planning target volumes mean 466 cc (range: 257–912), mean lung dose 7.36 Gy (range 3–8.9 Gy), spinal cord max dose to 0.1 cc mean 27.65 Gy (range 34.5–18 Gy). (See In Cohort A2, 10 out of the 18 (56%) patients who started treatment stopped their capecitabine treatment before the end. The main reasons for early stoppages were Disease Progression and Neutropenia, accounting for 70% (seven out of 10) of all stoppages. 70% (seven out of 10) stoppages occurred in the first two cycles of treatment. Nine out of the 18 (50%) patients who started treatment stopped their Cisplatin treatment before the end. The main reason for early stoppages was Disease Progression 67% (six out of nine) of all stoppages.In cohort A2, there were five SAEs in the cohort, occurring in three patients: pyrexia, neutropenia, sepsis, vomiting and chest pain. There were no treatment-related deaths.A summary of all the five most common MedDRA System Organ Classes affected by adverse events for both stages is presented in Table 